Related Experiment Video
Updated: Aug 12, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
How to analyze ex vivo T-cell responses in cancer patients
Dirk Nagorsen1, Francesco M Marincola
1Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892-1502, USA.
Abstract:
Tumor-associated antigens are present in several malignancies and represent promising targets for immunotherapeutic approaches. Antigen-specific CD8+ T-cells are an important component of immunosurveillance in malignant diseases as they recognize, target, and kill tumor cells. The induction of T-cells reactive against epitopes of tumor-associated antigens is the major immunological aim of several cancer vaccination trials. In recent years, significant progress has been made in developing methods to detect and characterize these antigen-specific T-cells. Here, we review and compare the most important techniques for specific T-cell analyses including cytokine-based functional assays, HLA class I/epitope tetrameric complexes, and PCR-based methods. We emphasize single cell methods and underline the importance of ex vivo methods without prior culturing.

